Postery

Web platforma spoločnosti Biogen venovaná problematike SM a SMA

Držiteľ rozhodnutia o registrácii: Biogen Netherlands B.V. Prins Mauritslaan 13, 1171 LP Badhoevedorp, Holandsko.

Kontakt v SR: Biogen Slovakia s.r.o., Karadžičova 12, 821 08 Bratislava, IČO: 36 363 146, IČO pre DPH: SK 2022192029, Obch. Reg. Okr. súdu Bratislava I., Odd: Sro, Vl.č. 4075/B. www.biogen.sk, medinfoslovakia@biogen.com

Hlásenie podozrení na nežiaduce reakcie www.sukl.sk v časti Bezpečnosť liekov/Hlásenie o nežiaducich účinkoch. Nežiaduci účinok môžete nahlásiť aj spoločnosti Biogen na emailovej adrese: sk-safety@biogen.com.

ECTRIMS 2022

SISTER–Subcutaneous: Non-interventional, observational, prospective, German multicenter, open label study over 12 months for Tysabri Patient Preference Experience from Real World –Preliminary results of the 1stinterim analysis

Natalizumab-treated RRMS Patients with Prior DMT Use Report Better Outcomes, Treatment Satisfaction, and Unique Benefits than Similar Patients Treated with Ocrelizumab

Exploratory Magnetic Resonance Imaging Endpoints from NOVA: A Randomised Controlled Study of the Efficacy of 6-week Dosing of Natalizumab vs Continued 4-week Treatment for Multiple Sclerosis

Clinical Effectiveness and Safety of Dimethyl fumarate for Patients Treated at least 6 Years in the Swedish post-market surveillance study “Immunomodulation and Multiple Sclerosis Epidemiology 5” (IMSE 5)

Reconstitution of Lymphocytes following discontinuation of Dimethyl fumarate (DMF) due to lymphopenia in the Swedish post-market surveillance study “Immunomodulation and Multiple Sclerosis Epidemiology 5” (IMSE 5)

Skrátená informácia o lieku

Web platforma spoločnosti Biogen venovaná problematike SM a SMA